2
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      The Breast Cancer Single-Cell Atlas: Defining cellular heterogeneity within model cell lines and primary tumors to inform disease subtype, stemness, and treatment options

      research-article

      Read this article at

          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Purpose

          Breast Cancer (BC) is the most diagnosed cancer in women; however, through significant research, relative survival rates have significantly improved. Despite progress, there remains a gap in our understanding of BC subtypes and personalized treatments. This manuscript characterized cellular heterogeneity in BC cell lines through scRNAseq to resolve variability in subtyping, disease modeling potential, and therapeutic targeting predictions.

          Methods

          We generated a Breast Cancer Single-Cell Cell Line Atlas (BSCLA) to help inform future BC research. We sequenced over 36,195 cells composed of 13 cell lines spanning the spectrum of clinical BC subtypes and leveraged publicly available data comprising 39,214 cells from 26 primary tumors.

          Results

          Unsupervised clustering identified 49 subpopulations within the cell line dataset. We resolve ambiguity in subtype annotation comparing expression of Estrogen Receptor, Progesterone Receptor, and Human Epidermal Growth Factor Receptor 2 genes. Gene correlations with disease subtype highlighted S100A7 and MUCL1 overexpression in HER2 + cells as possible cell motility and localization drivers. We also present genes driving populational drifts to generate novel gene vectors characterizing each subpopulation. A global Cancer Stem Cell (CSC) scoring vector was used to identify stemness potential for subpopulations and model multi-potency. Finally, we overlay the BSCLA dataset with FDA-approved targets to identify to predict the efficacy of subpopulation-specific therapies.

          Conclusion

          The BSCLA defines the heterogeneity within BC cell lines, enhancing our overall understanding of BC cellular diversity to guide future BC research, including model cell line selection, unintended sample source effects, stemness factors between cell lines, and cell type-specific treatment response.

          Supplementary Information

          The online version contains supplementary material available at 10.1007/s13402-022-00765-7.

          Related collections

          Author and article information

          Contributors
          arpit.dave@icahn.mssm.edu
          daniel.charytonowicz@icahn.mssm.edu
          nancy.francoeur@mssm.edu
          michael.beaumont@mssm.edu
          kristin.beaumont@mssm.edu
          hankschmidt@gmail.com
          tizita.zeleke@gmail.com
          jose.silva@mssm.edu
          robert.sebra@mssm.edu
          Journal
          Cell Oncol (Dordr)
          Cell Oncol (Dordr)
          Cellular Oncology (Dordrecht)
          Springer Netherlands (Dordrecht )
          2211-3428
          2211-3436
          4 January 2023
          4 January 2023
          2023
          : 46
          : 3
          : 603-628
          Affiliations
          [1 ]GRID grid.59734.3c, ISNI 0000 0001 0670 2351, Department of Genetics & Genomic Sciences, , Icahn School of Medicine at Mount Sinai, ; 1425 Madison Ave - Icahn (East) Building, Floor 14, Room 14-20E, New York, NY 10029 USA
          [2 ]GRID grid.59734.3c, ISNI 0000 0001 0670 2351, Icahn Genomics Institute, , Icahn School of Medicine at Mount Sinai, ; New York, NY 10029 USA
          [3 ]GRID grid.418019.5, ISNI 0000 0004 0393 4335, GlaxoSmithKline, ; Collegeville, PA 19426 USA
          [4 ]GRID grid.59734.3c, ISNI 0000 0001 0670 2351, Department of Pathology, , Icahn School of Medicine at Mount Sinai Hospital, ; New York, NY 10029 USA
          [5 ]GRID grid.59734.3c, ISNI 0000 0001 0670 2351, Black Family Stem Cell Institute, , Icahn School of Medicine at Mount Sinai, ; New York, NY 10029 USA
          [6 ]GRID grid.59734.3c, ISNI 0000 0001 0670 2351, Center for Advanced Genomics Technology, , Icahn School of Medicine at Mount Sinai, ; New York, NY 10029 USA
          [7 ]GRID grid.423340.2, ISNI 0000 0004 0640 9878, Pacific Biosciences, ; CA Menlo Park, USA
          Author information
          http://orcid.org/0000-0001-9267-2426
          Article
          765
          10.1007/s13402-022-00765-7
          10205851
          36598637
          f3085dce-d980-4ebb-949c-c14b0e7f1f72
          © The Author(s) 2022

          Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

          History
          : 13 December 2022
          Categories
          Original Article
          Custom metadata
          © Springer Nature Switzerland AG 2023

          Oncology & Radiotherapy
          breast cancer,scrnaseq,cell lines,stemness scoring,disease subtyping,therapeutic prediction

          Comments

          Comment on this article